Dinner Short Course*

*Separate registration required

Our short courses are designed to be instructional, interactive, and provide in-depth information on a specific topic. They allow for one-on-one interaction between the participants and instructors to facilitate the explanation of the more technical aspects that would otherwise not be covered during our main presentations.

The Short Course Will Be Offered In-Person Only

 

Tuesday, August 8, 2023  5:30 - 8:00 pm

SC2: Targeting Solid Tumors and Understanding the TME

Detailed Agenda
Tony R. Arulanandam, DVM, PhD, Consultant, Immuno-Oncology and Co-Founder NextPoint Therapeutics

IN PERSON ONLY SHORT COURSE

5:30 pm

IN PERSON ONLY: Targeting Solid Tumors and Understanding the TME: 

Tony R. Arulanandam, DVM, PhD, Consultant, Immuno-Oncology and Co-Founder NextPoint Therapeutics

  • ​Understanding the Tumor Microenvironment (TME)
  • The TME's role in immuno-oncology
  • Solid tumor biology
  • Targeting solid tumors
  • Latest approaches to solid tumors

INSTRUCTOR BIOGRAPHIES:

Tony R. Arulanandam, DVM, PhD, Consultant, Immuno-Oncology and Co-Founder NextPoint Therapeutics

Tony Arulanandam, DVM, PhD, Senior Vice President and Head of Preclinical Research and Development at Cytovia Therapeutics focused in developing NK Cell engager bispecific antibody and iPSC derived CAR-NK therapies for cancer. He is also the Co-Founder of NextPoint therapeutics, an MPM capital-funded IO checkpoint immunotherapy company. He is an immunologist with 20+ years of research and development experience developing multiple immunotherapies for autoimmune/inflammatory diseases and cancer (5 BLAs and multiple INDs). He is also currently a mentor for postdocs at the Dana-Farber Cancer Institute through the post-graduate association.





Preliminary Agenda

Conference Programs